Page 126 - Drug Class Review
P. 126
Page 93 of 205
Drug Effectiveness Review Project
Groups similar at baseline: No (gender distribution differed significantly)
galantamine 75.1 71.4 NR 74.6 3.2 Primary Outcome Measures: Physician’s and Caregiver’s Satisfaction Questionnaires (developed by Secondary Outcome Measures: ADAS-Cog 11; ADAS-Cog 13; MMSE; DAD (40-item) Timing of assessments: Weeks 4, 8 and 12; cognitive assessments at screening, weeks 4, 8 and 12 DON-treated patients had significantly better physician and caregiver satisfaction scores at Significantly greater improvement of DAD scores for DON than GAL- treated patients (P < 0.05) At endpoint DON-treated patients had significantly greater improvements on ADAS-Cog 1
Alzheimer classification: Mild-moderate
donepezil 73.8 51.6 NR 73.5 3.1 Health Outcome Measures: endpoint (P < 0.01). at endpoint ediate Outcome Measures:
Pfizer and Eisai) • • Interm • • •
Final Report Update 1 Authors: Jones et al. Year: 2004 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Other germane population qualities: Mean age onset AD diagnosis • Months since diagnosis • (median) OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
